ENCISION INC
Close on Oct 19, 2026
- Market cap
- $163.15K
- P/E (TTM)
- –
- Dividend yield
- –
About Encision
Surgical & Medical Instruments & Apparatus, SIC 3841
Encision Inc. designs, manufactures, and markets medical devices specializing in surgical instruments for minimally invasive laparoscopic procedures. The company’s patented Active Electrode Monitoring technology prevents stray electrosurgical energy and accidental burn injuries from insulation failure or capacitive coupling. Its product portfolio features shielded and monitored endo-mechanical instruments, including surgical scissors, graspers, dissectors, fixed-tip electrodes, and suction-irrigation electrodes, available in reusable and disposable designs. Encision also provides monitor units and smart cords such as the EndoShield 2 burn protection system, along with proof-of-concept surgical robotic services. Its customers primarily include hospitals, surgeons, and healthcare networks.
The company operates from its principal executive offices in Boulder, Colorado. Encision markets its instruments and monitors across the United States through direct sales representatives and independent distributors, while maintaining supplier agreements with group purchasing organizations and health systems. Internationally, the company sells through distributors in Australia and New Zealand and holds regulatory clearance to market products in Europe.
Summary of the business section of Encision's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ENCISION INC
- Founded
- 1991
- Headquarters
- Boulder, CO
- Address
- 6797 Winchester Circle 80301
- Phone
- (303) 444-2600
- Employees
- 24, Mar 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Colorado
- Fiscal year ends
- March 31
- Auditor
- Green Growth CPAs, Los Angeles, California
Stock & identifiers
- Ticker
- ECIA
- Exchange
- OTC
- Shares outstanding
- 17M, Nov 10, 2025
- Public float
- $2.72M, Sep 30, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 930775
- CUSIP
- 29254Q104
- ISIN
- US29254Q1040
- EIN
- 84-1162056
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert H. Fries | CEO, Director | 1,506,785 |
| Gregory J. Trudel | CEO, Director | 1,297,822 |
| Brian J. Jackman | VP of Marketing | 18,642 |
| Brandon Jason Shepard | VP of Finance | 1,000,000 |
| Peter D. Geary | Dir of Strategic Integation | 60,241 |
| Vern D. Kornelsen | Director | 3,206,249 |
| Patrick W. Pace | Director | 10,286 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Gregory J. Trudel | $303.14K | $279.63K | $183.38K | $70 | – |
| FY2024 Gregory J. Trudel | $267.40K | $288.21K | $158.32K | $75 | – |
| FY2023 Gregory J. Trudel | $264.05K | $179.66K | $150.81K | $62 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 31, 2025, we employed 22 full-time and 2 part-time individuals, of which 3 full-time and 1 part-time are engaged directly in research, development, and regulatory activities, 6 full-”
Corporate history
Events identified from SEC filings